Business context and reporting period
The supplied filing is Immudyne, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2016—not a LifeMD, Inc. filing. Immudyne develops and sells yeast beta-glucan immune-support products. Its business includes nutraceutical and cosmetic additives and, following an increase in ownership to 78.17%, consolidated finished cosmetic products operations through Immudyne PR LLC.
Financial results and liquidity
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Net sales | $1.23 million | $277,353 | $2.87 million | $565,630 |
| Gross profit (margin) | $526,270 (43%) | $187,850 (68%) | $829,356 (29%) | $401,911 (71%) |
| Operating loss | $153,632 | $17,170 | $258,728 | $9,336 |
| Net loss attributable to Immudyne | $199,976 | $21,028 | $262,025 | $19,362 |
- Six-month operating cash use was $76,662, compared with $56,433 in 2015. Financing provided $79,130, including a $79,130 investment in the subsidiary by noncontrolling interests. Cash was $235,452 at June 30, 2016, up from $232,984 at year-end 2015.
- Current assets were $865,781 and current liabilities $521,640, for working capital of about $344,000 and a current ratio of 1.6. Accounts receivable was $451,074 and inventory $179,255.
- Debt included a $100,000 commercial loan bearing 11% interest, due November 1, 2016. The filing also cites approximately $400,000 in customer holdbacks being released monthly.
- Stockholders’ equity totaled $344,141. Common shares outstanding rose from 32.01 million at year-end to 34.31 million at June 30; 2.3 million shares were issued to consultants for services.
Material changes versus the prior comparable period
- Sales increased sharply, principally because finished cosmetic products contributed $964,937 in Q2 and $2.34 million in the first half; that segment had no sales in the comparable 2015 periods. Additives sales were broadly stable.
- Gross margins declined substantially as the sales mix shifted toward finished cosmetics and the company incurred significant advertising and marketing costs. Management reported $1.16 million of up-front advertising and marketing expense for the first half.
- Operating expenses rose to $679,902 in Q2 and $1.09 million in the first half, driven in part by compensation, consultant share awards, and legal and accounting costs related to the joint venture. First-half stock-based compensation was $348,562.
- Customer discounts, returns and rebates were approximately $620,000 in Q2 and $1.05 million in the first half of 2016; these were not significant in 2015.
Outlook, risks and unusual items
- The filing states that the accumulated deficit was approximately $8.8 million and that negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. Management said it expected operations and short-term borrowings to fund operations through 2016, but may need higher sales or additional equity or debt financing; no assurance is given that financing will be available on acceptable terms.
- Management expects advertising and marketing costs to decline as a percentage of sales as the finished-products business matures. This is an expectation, not formal financial guidance.
- Disclosure controls and procedures were assessed as ineffective due to material weaknesses, including inadequate segregation of duties, insufficient written accounting and reporting policies, weak computer access and disaster-recovery controls, and no written whistleblower policy. Management said remediation depended on sufficient funds.
- The Kentucky plant lease expired May 31, 2016; operations continued month-to-month at approximately $9,000 monthly base rent while renewal options were discussed.
- Management reported no known legal proceedings expected to have a material adverse effect. Key business risks include financing needs, customer concentration, intellectual-property protection, regulation, and potential shareholder dilution. A major additives customer represented 16% of first-half sales and 30% of receivables at June 30.
Important facts for investors to verify
- Confirm the issuer: this document identifies Immudyne, Inc., despite the request metadata naming LifeMD, Inc.
- Assess the timing and collectability of the reported customer holdbacks, receivables, and rebates, and reconcile their effect on reported revenue and cash flow.
- Track whether the new finished-products segment can sustain sales and improve margins as marketing costs change.
- Verify the company’s ability to meet the November 2016 debt maturity and fund operations without further financing, and review any subsequent financing or dilution.
- Monitor remediation of the disclosed material weaknesses and the status of the Kentucky facility lease.